MARKET

CSBR

CSBR

Champions
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.75
0.00
0.00%
Closed 16:00 01/26 EST
OPEN
7.79
PREV CLOSE
7.75
HIGH
7.96
LOW
7.75
VOLUME
5.53K
TURNOVER
--
52 WEEK HIGH
14.68
52 WEEK LOW
7.75
MARKET CAP
104.74M
P/E (TTM)
292.45
1D
5D
1M
3M
1Y
5Y
Champions Oncology-Fannin team up to develop therapeutics for tumors
Champions Oncology (CSBR +0.1%) is collaborating with Fannin Innovation Studio to develop next generation therapeutics drug conjugates for tumors. The partnership will combine novel therapeutic targets identified within Champions' Lumin
Seekingalpha · 6d ago
Champions Oncology Announces Partnership With Fannin Innovation To Jointly Develop Therapeutic Raptamer Drug Conjugates
Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, announced today a therapeutic
Benzinga · 01/20 13:44
Champions Oncology Announces a Partnership with Fannin Innovation to Jointly Develop Therapeutic Raptamer Drug Conjugates
HACKENSACK, NJ / ACCESSWIRE / January 20, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, announced today a th...
ACCESSWIRE · 01/20 13:30
Champions Oncology Working With Fannin Innovation to Develop Tumor-Specific Therapies
MT Newswires · 01/20 10:40
Champions Oncology Announces Partnership With Alloy Therapeutics To Develop Therapeutic Monoclonal Antibodies For Use In ADC Programs
 Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative pharmacology, biomarker, and data platforms, announced today a therapeutic
Benzinga · 01/04 13:37
Champions Oncology's (NASDAQ:CSBR) investors will be pleased with their impressive 149% return over the last five years
It hasn't been the best quarter for Champions Oncology, Inc. ( NASDAQ:CSBR ) shareholders, since the share price has...
Simply Wall St. · 01/04 10:07
Looking Into Champions Oncology's Return On Capital Employed
According to Benzinga Pro, during Q2, Champions Oncology (NASDAQ:CSBR) earned $277.00 thousand, a 261.05% increase from the preceding quarter. Champions Oncology also posted a total of $11.79 million in sales, a 4.74% increase since Q1.
Benzinga · 12/14/2021 15:08
Champions Oncology EPS beats by $0.02, beats on revenue
Champions Oncology (NASDAQ:CSBR): FQ2 Non-GAAP EPS of $0.03 beats by $0.02; GAAP EPS of $0.02 beats by $0.01. Revenue of $11.79M (+16.5% Y/Y) beats by $0.24M. Press Release
Seekingalpha · 12/13/2021 21:22
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CSBR. Analyze the recent business situations of Champions through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CSBR stock price target is 15.67 with a high estimate of 17.00 and a low estimate of 14.00.
High17.00
Average15.67
Low14.00
Current 7.75
EPS
Actual
Estimate
-0.020.000.020.04
Q3 2021
  • 0
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 58
Institutional Holdings: 9.28M
% Owned: 68.66%
Shares Outstanding: 13.51M
TypeInstitutionsShares
Increased
8
79.79K
New
2
6.61K
Decreased
17
110.27K
Sold Out
5
353.35K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.76%
Pharmaceuticals & Medical Research
-0.46%
Key Executives
Non-Executive Chairman/Independent Director
Joel Ackerman
Chief Executive Officer/Director
Ronnie Morris
Chief Financial Officer
David Miller
Lead Director/Independent Director
David Sidransky
Director
Robert Brainin
Independent Director
Philip Breitfeld
Independent Director
Daniel Mendelson
Independent Director
Scott Tobin
No Data
About CSBR
Champions Oncology, Inc. is engaged in creating transformative technology solutions to be utilized in oncology drug discovery and development. This technology includes the Company’s in-vivo, ex-vivo and biomarker platforms, oncology software solutions, and computational-based discovery platforms. The Company’s TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology. The Company’s software as a service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. The Company’s drug discovery and development business leverages the computational and experimental capabilities within its platforms. Their discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify novel therapeutic targets.

Webull offers kinds of Champions Oncology Inc stock information, including NASDAQ:CSBR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CSBR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CSBR stock methods without spending real money on the virtual paper trading platform.